tailieunhanh - Báo cáo hóa học: " Erythropoietin (EPO) in acute kidney injury"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Erythropoietin (EPO) in acute kidney injury | Moore and Bellomo Annals of Intensive Care 2011 1 3 http content 1 1 3 o Annals of Intensive Care a SpringerOpen Journal REVIEW Open Access Erythropoietin EPO in acute kidney injury Elizabeth Moore Rinaldo Bellomo Abstract Erythropoietin EPO is a kDa glycoprotein produced by the kidney and is mostly well-known for its physiological function in regulating red blood cell production in the bone marrow. Accumulating evidence however suggests that EPO has additional organ protective effects which may be useful in the prevention or treatment of acute kidney injury. These protective mechanisms are multifactorial in nature and include inhibition of apoptotic cell death stimulation of cellular regeneration inhibition of deleterious pathways and promotion of recovery. In this article we review the physiology of EPO assess previous work that supports the role of EPO as a general tissue protective agent and explain the mechanisms by which it may achieve this tissue protective effect. We then focus on experimental and clinical data that suggest that EPO has a kidney protective effect. Introduction Erythropoietin EPO is a complex molecule which regulates red blood cell production in the bone marrow. Recombinant human EPO rHuEPO is commercially available and is widely used for the treatment of anemia. In recent years additional nonerythropoietic tissue organ protective properties of EPO have become apparent in particular for kidneys. In this article we consider the evidence supporting EPO as a general tissue protective drug and discuss the potential mechanisms by which it may achieve this general effect. We then focus on the renal protective effects of EPO and the potential mechanisms through which it may confer this specific protection. Finally we review the experimental studies and clinical trials of EPO in acute kidney injury AKI - discuss risks lessons learned and the need for further randomized studies in humans before any change in .